ExpreS2ion Biotech secured crucial approval for Phase I clinical trial of ES2B-C001, their novel HER2-expressing breast cancer therapeutic vaccine, marking their entry into clinical development.
A phase 2b trial in Burkina Faso demonstrates the RH5.1/Matrix-M malaria vaccine's safety and efficacy, showing a 55% vaccine efficacy in a delayed third-dose regimen among children aged 5-17 months.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.